tiprankstipranks
Trending News
More News >

Invion Announces $1 Million Entitlement Offer for Eligible Shareholders

Story Highlights
  • Invion is a life-science company developing Photosoft™ technology for cancer and infectious diseases.
  • Invion launches a $1 million entitlement offer for eligible shareholders in select regions.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Invion Announces $1 Million Entitlement Offer for Eligible Shareholders

Don’t Miss TipRanks’ Half-Year Sale

An update from Invion ( (AU:IVX) ) is now available.

Invion Limited has announced a fully underwritten, non-renounceable entitlement offer to raise approximately $1 million. The offer is available only to eligible shareholders in Australia, New Zealand, and Hong Kong, and involves issuing new options with specific exercise prices and expiry dates. This move is part of Invion’s strategy to strengthen its financial position and support its ongoing projects in the life-science sector.

More about Invion

Invion is a life-science company focused on the research and development of Photosoft™ technology, which is used for treating various cancers, atherosclerosis, and infectious diseases. The company holds exclusive rights to this technology in Australia, New Zealand, Hong Kong, and other parts of Asia Pacific, excluding certain regions. Invion’s research and clinical trials are funded by RMW Cho Group Limited, and it is listed on the ASX.

YTD Price Performance: -55.36%

Average Trading Volume: 101,227

Technical Sentiment Signal: Sell

Current Market Cap: A$10.59M

For a thorough assessment of IVX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1